QuickStrip

Rapid Dose Therapeutics is advancing the next phase of its Burlington facility expansion targeting global medical markets to strengthen pharmaceutical manufacturing capability, support future regulatory pathways, and expand the long-term strategic value of its QuickStrip™ platform.

This is more than a facility upgrade. It is a disciplined investment in infrastructure designed to support scale, flexibility, and future participation in regulated global medical markets.

Why this matters:
• Global prescription drug sales are forecast to reach approximately US$1.7 trillion by 2030.
• The global medical cannabis market is projected to reach approximately US$65.9 billion by 2030.
• As demand grows for compliant, non-combustible, patient-friendly delivery formats, manufacturing readiness becomes a strategic advantage.

https://rapid-dose.com/rapid-dose-therapeutics-cse-dose-otcqb-rdtcf-advances-pharmaceutical-manufacturing-expansion-with-burlington-facility-upgrades-targeting-global-medical-markets/

Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) Advances Pharmaceutical Manufacturing Expansion with Burlington Facility Upgrades Targeting Global Medical Markets - Rapid Dose Therapeutics BURLINGTON, ON — April 13, 2026 — Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) (“RDT” or the “Company”), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at i...

Major Patent Milestone!

Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) Secures Patent for QuickStrip™ Ni****ne Oral Film Targeting $38B Smoke-Free Ni****ne Market

Key Highlights for Investors:

• Massive Addressable Market: The global modern oral ni****ne market is projected to reach $38.89 Billion by 2033, growing at a 19% CAGR.

• Global IP Footprint: This grant follows our 2025 WIPO PCT filing, extending potential protection to up to 158 jurisdictions worldwide.

• Strategic Advantage: Partnered with Aavishkar Oral Strips, we are positioned to disrupt traditional ni****ne delivery with a discreet, smoke-free alternative.

• Ongoing Discussions: RDT remains engaged in commercial discussions with a major global ni****ne company, a relationship now backed by stronger IP.

Read the full press release here:
https://rapid-dose.com/rapid-dose-therapeutics-cse-dose-otcqb-rdtcf-secures-patent-for-quickstrip-ni****ne-oral-film-targeting-38b-smoke-free-ni****ne-market/

****neReplacement $DOSE $RDTCF

Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) Secures Patent for QuickStrip™ Ni****ne Oral Film Targeting $38B Smoke-Free Ni****ne Market - Rapid Dose Therapeutics BURLINGTON, Ontario — March 5, 2026 — Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, today announced the grant of a key patent for its QuickStrip™ Ni****ne Bilayer Oral Film in partnership with...

Rapid Dose Therapeutics advances cannabinoid research and clinical evaluation of its proprietary QuickStrip™ oral thin film delivery platform. Independent studies, supported by grant funding, are exploring cannabinoids’ role in pain management and neuroprotection related to concussion and participation in contact sports, while a clinical arm is assessing CBD bioavailability vs traditional oral formats.

https://www.newsfilecorp.com/release/284877

$DOSE $RDTCF

Rapid Dose Therapeutics Advances Cannabinoid Research and Clinical Evaluation of QuickStrip(TM) Platform Burlington, Ontario--(Newsfile Corp. - February 23, 2026) - Rapid Dose Therapeutics Corp. ...

🚨 INVESTOR ALERT: Aegis Research sees $1.00 path for Rapid Dose Therapeutics Corp (CSE: $DOSE | OTCQB: $RDTCF). 80% bioavailability tech + 45% sales growth
Watch: https://youtu.be/nbX0dLxSllM

$DOSE $RDTCF

Aegis Research RDT Analysis Overview of Rapid Dose Therapeutics (CSE: DOSE) (OTC: RDTCF) and its proprietary QuickStrip We are not Financial Advisers and Do Your Own Research. Aegis R...

RDT advances NicStrip(TM) commercialization with $1.8 million CAD extension

https://www.newsfilecorp.com/release/271072

****neAlternatives ****neMarket $DOSE

Rapid Dose Therapeutics Releases Ni****ne Business Update and Extends Collaboration with International Ni****ne Partner Burlington, Ontario--(Newsfile Corp. - October 20, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian...

Rapid Dose Therapeutics Submits QuickStrip™ Ni****ne Product for Health Canada Approval

Innovative Oral Ni****ne Delivery Technology Targets Safer Alternative for Smokers

https://shorturl.at/REOZu

****neAlternative ****ne ****neInnovation

Rapid Dose Therapeutics Submits QuickStrip™ Ni****ne Product for Health Canada Approval - Rapid Dose Therapeutics Innovative Oral Ni****ne Delivery Technology Targets Safer Alternative for Smokers Burlington, ON – August 4, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian life sciences company focused on innovative drug delivery technologies, is pleased to announ...

Rapid Dose Therapeutics and Eco Canadian Organic Inc. Initiate Health Canada Funded SUAP Harm Reduction Pilot Project on First Nations Using QuickStrip™ to Combat **te Crisis

https://shorturl.at/O4JX6

Rapid Dose Therapeutics and Eco Canadian Organic Inc. Initiate Health Canada Funded SUAP Harm Reduction Pilot Project on First Nations Using QuickStrip™ to Combat Op**te Addiction Crisis - Rapid Dose Therapeutics Burlington, Ontario – July 29, 2025– Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company, is proud to announce the launch of a new significant harm reduction initiative aimed at addressing the devastating opioid crisis gripping Canada’s ...

Patented Innovation in Ni****ne Delivery

Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Ni****ne Delivery Technology.

These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use.

https://rapid-dose.com/rapid-dose-therapeutics-and-aavishkar-oral-strips-file-two-key-patents-for-innovative-ni****ne-delivery-technology/

****neInnovation $DOSE

Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Ni****ne Delivery Technology - Rapid Dose Therapeutics BURLINGTON, ON – May 26, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian life sciences company specializing in innovative drug delivery solutions through its QuickStrip™ platform, today announced the filing of two critical patent applications in pa...

Today on this Remembrance Day, we commemorate and honor the courage, sacrifice, and resilience of those who have served and continue to serve.

Lest we forget.